Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus

Cardiovascular Risk ◽

Risk Reduction ◽

Young Patients ◽

Dipeptidyl Peptidase 4 ◽

Recent Insights into Pharmacologic Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus

Cardiovascular Drugs and Therapy ◽

10.1007/s10557-017-6750-1 ◽

2017 ◽

Vol 31 (4) ◽

pp. 459-470 ◽

Cited By ~ 3

Author(s):

Scott L. Purga ◽

Mandeep Sidhu ◽

Michael Farkouh ◽

Joshua Schulman-Marcus

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Cardiovascular Risk ◽

Risk Reduction ◽

Cardiovascular Risk Reduction

Sodium-Glucose Co-transporter 2 Inhibitor: A Perspective on Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus

Hypertension Journal ◽

10.5005/jp-journals-10043-0046 ◽

2016 ◽

Vol 2 (3) ◽

pp. 139-144

Author(s):

Gary E Sander ◽

Camilo Fernandez ◽

Philip J Kadowitz ◽

Thomas D Giles

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Cardiovascular Risk ◽

Risk Reduction ◽

Cardiovascular Risk Reduction

Sodium-Glucose Co-Transporter 2 Inhibitors and the Potential for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes Mellitus

Postgraduate Medicine ◽

10.3810/pgm.2013.05.2654 ◽

2013 ◽

Vol 125 (3) ◽

pp. 21-32 ◽

Cited By ~ 17

Author(s):

Robert M. Guthrie

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Cardiovascular Risk ◽

Risk Reduction ◽

Cardiovascular Risk Reduction

Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review

Mayo Clinic Proceedings ◽

10.1016/j.mayocp.2018.07.018 ◽

2018 ◽

Vol 93 (11) ◽

pp. 1629-1647 ◽

Cited By ~ 14

Author(s):

Salvatore Carbone ◽

Dave L. Dixon ◽

Leo F. Buckley ◽

Antonio Abbate

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Cardiovascular Risk ◽

Risk Reduction ◽

State Of The Art ◽

Glucose Lowering

Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?

Current Cardiology Reports ◽

10.1007/s11886-018-1051-2 ◽

2018 ◽

Vol 20 (11) ◽

Cited By ~ 11

Author(s):

Yixing Li ◽

Paul D. Rosenblit

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Cardiovascular Risk ◽

Risk Reduction ◽

Class Effect ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Weight Management for Type 2 Diabetes Mellitus: Global Cardiovascular Risk Reduction

The American Journal of Cardiology ◽

10.1016/j.amjcard.2006.11.007 ◽

2007 ◽

Vol 99 (4) ◽

pp. 68-79 ◽

Cited By ~ 49

Author(s):

Michelle Lee ◽

Louis J. Aronne

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Cardiovascular Risk ◽

Risk Reduction ◽

Weight Management ◽

Global Cardiovascular Risk

The dipeptidyl peptidase-4 inhibitor vildagliptin does not affect ex vivo cytokine response and lymphocyte function in patients with type 2 diabetes mellitus

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2013.12.039 ◽

2014 ◽

Vol 103 (3) ◽

pp. 395-401 ◽

Cited By ~ 12

Author(s):

P.C.M. van Poppel ◽

M.S. Gresnigt ◽

P. Smits ◽

M.G. Netea ◽

C.J. Tack

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Ex Vivo ◽

Dipeptidyl Peptidase ◽

Cytokine Response ◽

Lymphocyte Function ◽

Dipeptidyl Peptidase 4 ◽

First-in-Human, Single-Ascending Dose and Food Effect Studies to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cetagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

Clinical Drug Investigation ◽

10.1007/s40261-021-01088-5 ◽

2021 ◽

Author(s):

Lu Wang ◽

Jinmiao Lu ◽

Sufeng Zhou ◽

Yuqing Zhao ◽

Lijun Xie ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Food Effect ◽

Dipeptidyl Peptidase ◽

Pharmacokinetics And Pharmacodynamics ◽

Dipeptidyl Peptidase 4 ◽

Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose combination

Expert Opinion on Pharmacotherapy ◽

10.1517/14656566.2014.939070 ◽

2014 ◽

Vol 15 (13) ◽

pp. 1785-1795 ◽

Cited By ~ 2

Author(s):

Yuri Ono ◽

Hikaru Kamoshima ◽

Akinobu Nakamura ◽

Hiroshi Nomoto

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Japanese Patients ◽

Metabolic Responses ◽

Fixed Dose ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Dose Combination

Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin

Hypertension ◽

10.1161/hypertensionaha.116.07797 ◽

2016 ◽

Vol 68 (3) ◽

pp. 606-613 ◽

Cited By ~ 17

Author(s):

William B. White ◽

Craig A. Wilson ◽

George L. Bakris ◽

Richard M. Bergenstal ◽

Christopher P. Cannon ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Angiotensin Converting Enzyme ◽

Angiotensin Converting Enzyme Inhibitor ◽

Enzyme Inhibitor ◽

Converting Enzyme ◽

Dipeptidyl Peptidase 4 ◽